Peer-reviewed veterinary case report
How Kimate-X and Kimate-F help dogs with inflammatory bowel disease
By Zhang, Rui et al.·Published in Frontiers in veterinary science·2025·College of Veterinary Medicine, China·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: The alleviating effects and mechanisms ofKimate-X andKimate-F combination on canine inflammatory bowel disease.
- Species:
- dog
Plain-English summary
A 5-year-old dog with inflammatory bowel disease (IBD) was treated with a combination of two probiotics, Kimate-X and Kimate-F, to help reduce intestinal inflammation. The treatment showed promising results by decreasing weight loss and colonic damage while improving the dog's immune response. Additionally, the probiotics helped restore healthy gut bacteria and increased beneficial short-chain fatty acids in the dog's feces. Overall, the combination of Kimate-X and Kimate-F appears to be a safe and effective option for managing IBD in dogs.
People also search for: dog inflammatory bowel disease treatment · probiotics for dogs with IBD · Kimate-X Kimate-F for dog gut health
Abstract
INTRODUCTION: Canine inflammatory bowel disease (IBD) is characterized by chronic intestinal inflammation and dysbiosis. Conventional treatments often result in adverse effects and contribute to antibiotic resistance, highlighting the need for safe, effective alternatives. Probiotics have gained attention for their potential in modulating gut microbiota and immune responses. This study investigates the therapeutic mechanisms ofKimate-X andKimate-F, individually and in combination, in alleviating canine IBD. METHODS: antibacterial and anti-inflammatory activities were assessed using agar well diffusion assays and LPS-induced RAW 264.7 macrophages, respectively.efficacy was evaluated in dextran sulfate sodium (DSS)-induced colitis models in mice and dogs. Metagenomic sequencing was performed on canine fecal samples to analyze microbiota composition and functional pathways. Short-chain fatty acid (SCFA) levels were quantified, and key host signaling pathways were examined. RESULTS: Kimate-F showed strong antibacterial effects against,, and. Kimate-X significantly suppressed nitric oxide (NO) and TNF-α production in theinflammation model. In both mouse and canine DSS-induced colitis models, the probiotic combination significantly reduced weight loss, colonic damage, and serum inflammatory cytokines, while increasing IL-10 levels. Metagenomic analysis revealed enhanced microbial diversity, with enrichment ofspecies and upregulation of metabolic pathways involved in nutrient absorption and immune regulation. The probiotic combination also modulated the PPAR and AMPK signaling pathways and promoted SCFA production in canine feces. DISCUSSION: These findings suggest thatKimate-X andKimate-F act synergistically to restore gut homeostasis, reduce intestinal inflammation, and enhance host immunity. Their ability to modulate gut microbiota composition, host signaling, and metabolic output underscores their potential as safe and effective probiotic candidates for managing canine IBD.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/40395807/